M035 trastuzumab desensitization protocol: a therapeutic challenge in a patient with metastatic breast cancer

Trastuzumab is a humanized mouse IgG1 mAb with selective affinity for the human EGF2 protein, HER-2, approved for the treatment of metastatic breast cancer. Rates of hypersensitivity reaction range from 0.6 to 5%.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research